Pulmonology Clinic Trends 2026: CPAP Moves from Volume to Continuity

Pulmonology clinics face a two-sided environment: demand is a tailwind while cost and regulation are headwinds.

On demand, ageing continues to drive COPD, pneumonia, and interstitial lung disease; asthma and allergic conditions supply a steady chronic patient base; and undiagnosed sleep apnea remains a large addressable population. The pandemic also normalized the behavior of seeking a specialist for respiratory symptoms, making differentiation from general internal medicine easier.

1. Macro environment — cost and regulatory headwinds

In the Reiwa 8 revision, the outpatient and home care base-up evaluation fee (I) rose from 6 to 17 points at first visit and from 28 to 79 points for visiting care, with a new 2-point inflation response fee added to first and return visits. Read the other way, this signals cost structures compressed enough that fee schedules are retroactively compensating for wage and property cost increases.

The healthcare DX promotion readiness add-on and related items were abolished and consolidated into an "electronic clinical information coordination readiness add-on" (up to 15 points at first visit), with cybersecurity measures made a requirement — digital readiness is becoming a billing condition in itself.

The lifestyle disease management fee was also revised, making blood testing at least once every six months mandatory under fee (I). Base points were held (fee I: 610 dyslipidemia / 660 hypertension / 760 diabetes; fee II: 333), but the requirements safeguarding management quality were tightened.

2. Characteristics of newly opened clinics

The defining feature of a new pulmonology practice is heavy initial investment. Infection control requires separated waiting areas, multiple consultation rooms, and a testing room, putting the floor area requirement at 150 m² or more. At 165 m², estimates run to roughly ¥45 million interior, ¥23 million equipment, and ¥27 million working capital — about ¥95 million — with CT adding another ¥25 million, pushing opening capital past ¥100 million. That load is a barrier to entry and, simultaneously, a source of differentiation.

Standard equipment includes X-ray and CT (with AI-assisted double reading), spirometry, exhaled nitric oxide measurement, and simplified sleep apnea testing. Together these enable definitive diagnosis and ongoing management of asthma, COPD, and SAS entirely in-house — difficult for a general internal medicine practice to match.

Three patterns stand out among new openings:

1. Urban clinics specializing in SAS/CPAP — practices branded as "sleep and respiratory medicine" centered on home CPAP management. These pair well with web booking and online return visits, and build recurring revenue as CPAP management fees accumulate
2. Declaring "allergy and respiratory medicine" — capturing year-round demand from persistent cough, hay fever, and sublingual immunotherapy
3. Designing fever and infection clinic flows from day one — separate entrances and time-slot booking are now standard

All three combine recurring chronic management with episodic acute and infectious care to smooth revenue.

3. Revenue areas specific to pulmonology

Asthma and COPD: inhaler technique and ongoing management

A textbook recurring revenue area built on inhaler instruction and regular follow-up. Alongside standard inhaled corticosteroid therapy, biologics for severe cases are changing both clinical quality and unit price. Multiple biologics are now used selectively in severe asthma, and adaptation continues to expand — Dupixent gained a COPD indication in 2025.

That said, high drug costs limit the eligible population, and some observers note the clinical impact remains contained. For a clinic, the realistic foundation is assuring inhaler technique quality and continuation rates.

CPAP home management for sleep apnea

One of pulmonology's revenue pillars, and the area that moved most in the Reiwa 8 revision.

The add-on's facility standards are outcome- and adherence-linked: use of devices capable of remotely monitoring usage time and AHI, and months with 20+ days of 4+ hour usage making up at least 40% of managed months over the preceding three months.

The management implication is unambiguous: evaluation moved from "patients started" to "continuation and adherence." Using remote monitoring to make usage data visible and raise continuation rates is now essential for both billing and retention. Sleep apnea has a large undiagnosed population, so building the pathway — simplified testing, detailed testing, CPAP initiation, remote follow-up — creates stable recurring revenue.

Smoking cessation clinics

Supply-side factors destabilized the insured model here. After varenicline (Champix) shipments halted and production ended, insured smoking cessation treatment became effectively unavailable for a period, pushing clinics toward nicotine patches or self-pay approaches. Resumption of distribution has since been reported. It aligns well with COPD management and works as an acquisition hook, but dependence on drug supply makes it unsuitable as a revenue pillar — treat it as supplementary.

Persistent cough and allergy

Persistent and chronic cough, plus seasonal and perennial allergy, are entry-point demands that differentiate pulmonology from general internal medicine and ENT. Differentiating cough-variant asthma and atopic cough via exhaled NO and spirometry demonstrates specialization, and creates a pathway from entry point into recurring asthma management and sublingual immunotherapy.

Home oxygen therapy (HOT)

A home management area covering COPD, interstitial lung disease, and chronic respiratory failure, generating ongoing management revenue including device add-ons. Discussion around the 2026 revision points to expanded at-home options including high-concentration oxygen and high-flow therapy, increasing HOT's role as the receiving point for severe and elderly patients shifting to home care. As with CPAP, remote monitoring and multidisciplinary and visiting care coordination are the keys.

Fever clinics and lung cancer screening

Fever and infection clinics moved from temporary response to permanent workflow. Separate entrances, time-slot booking, and online questionnaires have standardized, and combining episodic influenza and COVID revenue with recurring chronic management smooths seasonality.

Lung cancer screening and chest imaging leveraging CT and X-ray are also established for both revenue and acquisition. Low-dose CT with AI double reading is used in screening, creating a pathway where patients from municipal and corporate programs flow into clinical care when findings appear.

4. Self-pay services

Self-pay in pulmonology raises unit price and captures demand outside insurance at the periphery of insured practice.

The main case is allergen immunotherapy (sublingual immunotherapy, SLIT). SLIT for cedar and dust mite allergy is itself insured, but roughly 80% of patients see benefit (about 20% resolution, 60% symptom reduction) and it requires a minimum of three and typically four to five years of continuation — producing recurring patients who keep coming back over years. Around that long relationship, uninsured allergy testing and constitutional support menus can be positioned.

The other trend is adding general internal medicine self-pay menus: high-dose vitamin C and vitamin injections, AGA, medical weight loss, and supplements. These transfer easily across specialties and serve as revenue independent of fee points, supplementing margins squeezed by wage and cost inflation.

That said, self-pay design should center on SLIT-adjacent services connected to the clinic's specialization, treating aesthetic and anti-ageing offerings as pure margin supplement — a design that does not contradict the clinic's brand.

5. Management implications

Pulmonology economics reduce to thickening both layers: flow (fever, infection, acute cough) and stock (asthma, COPD, SAS, HOT, SLIT).

• CPAP moves from volume to continuity — the new enhanced management add-on makes adherence (4+ hour usage rate) and remote monitoring conditions for both billing and retention. Whether usage data visibility and outreach can be systematized is the dividing line
• Convert heavy equipment into differentiation — turn the ¥100m+ investment in CT, spirometry, exhaled NO, and SAS testing into diagnostic authority and in-house continuity that competitors cannot match
• Connect entry demand to recurring care — designing the path from persistent cough, hay fever, and fever clinics into asthma management, SLIT, and CPAP raises lifetime value
• Requirements are operational problems — mandatory blood testing and cybersecurity requirements mean continued billing depends on administrative and system design
• Keep self-pay on the specialty axis — center on SLIT; treat IV drips and AGA as margin supplement

6. How an AI EMR addresses these problems — feature by feature

In pulmonology, chronic management documentation repeats endlessly, CPAP device data feeds directly into billing requirements, and seasonality loads the front desk. Here is how Pottech's AI Karte works on all three, feature by feature.

Feature 1: Integrations and APIs — CPAP usage data is the add-on

An OAuth2 gateway, MCP server, and HAPI FHIR enable integration with external systems and devices.

The CPAP enhanced management add-on's facility standards require devices capable of remotely monitoring usage time and AHI, plus a track record threshold — months with 20+ days of 4+ hour usage making up at least 40% of the preceding three months. That only works if device data is ingested continuously and aggregated across patients. Without device integration you cannot demonstrate compliance with this add-on at all. Oxygen flow management in HOT has the same structure.

Feature 2: Billing and claims — watch deadlines and track records automatically

An automated calculation engine checks bundling conflicts, exclusions, and frequency limits, and determines add-on eligibility automatically.

CPAP fee 2 now carries the condition that billing is barred if average daily use falls under one hour across three consecutive months. Lifestyle disease management fee (I) requires blood testing at least every six months. Both are requirements where eligibility cannot be judged without tracking each patient's period and track record continuously. Running this on paper and staff memory breaks down as patient volume grows.

Feature 3: Charting and orders — compress repetitive structured documentation

AI generates SOAP notes from consultation audio, and web and paper questionnaires are digitized by camera. Set orders enter tests and prescriptions in one action.

Chronic management records — asthma control status, inhaler technique checks, CPAP usage hours, HOT oxygen flow — are highly structured, making them an excellent fit for templates plus AI voice input. Inhaler instruction is inherently "confirm and document the same things every visit," so reducing documentation effort directly buys back instruction time.

Feature 4: Booking and reception — separate fever flows from recurring patients

In-person and online bookings are managed together with segmented slot management.

A pulmonology front desk absorbs fever patients during infection season at the same time as chronic patients coming in for asthma, CPAP, and SLIT. Separating those two physically and temporally is infection control — and simultaneously a measure to prevent chronic patient dropout. When visits break during crowded periods, recurring revenue is lost with them. Whether time-slot booking and separate routing can be enforced by the booking system determines your capacity to absorb seasonality.

Feature 5: Patient PHR app integration ("Pote-kun") — support four to five years of continuity

Medication reminders, appointment booking, pre-visit web questionnaires, and LINE login with push notifications.

Sublingual immunotherapy requires a minimum of three and typically four to five years. CPAP is lifelong. In treatments that depend on patient self-management over horizons this long, visit and medication reminders determine both clinical outcomes and revenue. Returning CPAP usage feedback to the patient is a direct lever for meeting the add-on's track record requirement of 40% adherence months.

Feature 6: Practice analytics — view flow and stock separately

Visit volume, revenue per patient, monthly trends, and patient attributes are aggregated and visualized automatically.

Pulmonology revenue has two layers: episodic flow that swings with the season, and stable stock from asthma, COPD, SAS, HOT, and SLIT. Looking only at combined revenue leaves you unable to tell whether a good quarter came from an infection wave or from genuine growth in recurring patients. Tracking net growth in the recurring patient base as an independent metric is the foundation of management judgment in this specialty.

Primary sources

• Cosmos Pharmaceutical, "Opening, growing, and differentiating a pulmonology clinic" https://www.cosmospc.co.jp/clinic-support/column/archives/2025/08/column613.php
• Medical CPA, "FY2026 revision: lifestyle disease management fee changes" https://med-cpa.jp/hoshu-13/
• Yuyama, "Key points of the FY2026 revision for independent physicians" https://www.yuyama.co.jp/column/medicalrecord/revision-of-medical-fees-2026-2/
• Credo, "FY2026 revision: home CPAP management fee changes" https://www.credo-m.co.jp/column/detail/hosyu/25383/
• Zone Inc., "CPAP continuity management under the 2026 revision" https://zonekk.com/journal/442/
• Japan Society for Tobacco Control, "Champix shipment status" http://www.jstc.or.jp/modules/information/index.php?content_id=506
• Nikkei Medical, "How biologics are changing severe asthma and COPD care" https://medical.nikkeibp.co.jp/leaf/all/report/Weekly/202506/589154.html
• Sanofi, "Dupixent COPD indication approval" (March 27, 2025) https://www.sanofi.co.jp/assets/dot-jp/pressreleases/2025/250327.pdf